Adalimumab is a fully human, high-affinity, recombinant anti-tumor necrosis factor (TNF) alpha monoclonal antibody used to treat rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn disease, ulcerative colitis, etc. This activity covers the indications, mechanism of action, dosing, contraindications, and adverse events of this drug, as needed by the interprofessional healthcare team members to utilize it effectively for patient treatment.

**Objectives:**
- Summarize the mechanism of action of adalimumab.
- Describe the potential adverse effects of adalimumab.
- Review the appropriate monitoring for patients on adalimumab.
- Outline interprofessional team strategies for improving care coordination and communication when adalimumab is being administered.